New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAM™ pivotal trial. In separate post hoc analysis of pooled data from phase 3 RADIANCE™ Part B and SUNBEAM trials, ozanimod reduced annualized relapse rates and MRI lesions at 12 months in patients with a disease state defined as early relapsing multiple sclerosis compared with patients with more advanced disease.